drugset
drugset / Trial / NCT06641648

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

NCT06641648 ↗

Phase 1 Not yet recruiting 12 enrolled Peking University First Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Timeline

Start
2024-12-01
Primary completion
2025-12-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Donor NK Cells Cell therapy 1e+08 cells —
Subject Donor NK Cells Cell therapy 5e+08 cells —
Subject Donor NK Cells Cell therapy 2e+09 cells —

Indications

acute myeloid leukemia